RecruitingNCT05802836
Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
Sponsor
Christoph Königs
Enrollment
100 participants
Start Date
Apr 26, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.
Eligibility
Inclusion Criteria3
- Severe congenital hemophilia A (CHA)
- Treatment with emicizumab irrespective of any other treatment
- Informed consent
Exclusion Criteria3
- No therapy with emicizumab
- Immunosuppressive therapy
- HIV-infection with CD4 (cluster of differentiation 4) cells <200/µl
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERno interventions
no intervention, only 3 different patients groups
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05802836
Related Trials
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
NCT0768489819 locations
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
NCT0766390324 locations
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
NCT067036067 locations
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
NCT0593535818 locations
A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)
NCT059812741 location